losartan has been researched along with Becker Muscular Dystrophy in 10 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice." | 5.37 | Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011) |
| "The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)." | 2.58 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. ( Bourke, JP; Bueser, T; Quinlivan, R, 2018) |
| "Losartan has been reported to improve ASC transplantation in injured mouse muscles." | 1.42 | Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice. ( Hwang, M; Jeong, KS; Kim, AY; Kim, CY; Kim, SY; Lee, EJ; Lee, EM; Lee, MM; Park, JK, 2015) |
| " Although many researchers have demonstrated that losartan has anti-fibrotic and protective effects on cardiac and skeletal muscles, for long-term administration to treat dystrophic disorders, it is essential to demonstrate not only the therapeutic effects of losartan on muscles but also its effects on other organs and on blood biochemistry." | 1.42 | Chronic effects of losartan on the muscles and the serologic profiles of mdx mice. ( Jeong, KS; Kim, AY; Kim, DY; Kim, SH; Lee, EJ; Lee, EM; Lee, MM; Park, JK; Sung, SE, 2015) |
| "Various attempts have been made to find treatments for Duchenne muscular dystrophy (DMD) patients." | 1.40 | Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice. ( Hwang, M; Jeong, KS; Kang, KK; Kim, AY; Kwon, SH; Lee, EJ; Lee, EM; Lee, MM; Min, CW; Park, JK; Tremblay, JP, 2014) |
| "Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice." | 1.37 | Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourke, JP | 1 |
| Bueser, T | 1 |
| Quinlivan, R | 1 |
| Meyers, TA | 1 |
| Heitzman, JA | 1 |
| Krebsbach, AM | 1 |
| Aufdembrink, LM | 1 |
| Hughes, R | 1 |
| Bartolomucci, A | 1 |
| Townsend, D | 1 |
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Lee, EM | 3 |
| Kim, AY | 3 |
| Lee, EJ | 3 |
| Park, JK | 3 |
| Lee, MM | 3 |
| Hwang, M | 2 |
| Kim, CY | 1 |
| Kim, SY | 1 |
| Jeong, KS | 3 |
| Min, CW | 1 |
| Kang, KK | 1 |
| Kwon, SH | 1 |
| Tremblay, JP | 1 |
| Kim, DY | 1 |
| Kim, SH | 1 |
| Sung, SE | 1 |
| Spurney, CF | 1 |
| Sali, A | 1 |
| Guerron, AD | 1 |
| Iantorno, M | 1 |
| Yu, Q | 1 |
| Gordish-Dressman, H | 1 |
| Rayavarapu, S | 1 |
| van der Meulen, J | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Cohn, RD | 1 |
| van Erp, C | 1 |
| Habashi, JP | 1 |
| Soleimani, AA | 1 |
| Klein, EC | 1 |
| Lisi, MT | 1 |
| Gamradt, M | 1 |
| ap Rhys, CM | 1 |
| Holm, TM | 1 |
| Loeys, BL | 1 |
| Ramirez, F | 1 |
| Judge, DP | 1 |
| Ward, CW | 1 |
| Dietz, HC | 1 |
| Chamberlain, JS | 1 |
| Kuehn, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
1 review available for losartan and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2018 |
9 other studies available for losartan and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Acute AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathies; Dystrophin; Heart; Humans; Isopr | 2019 |
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice.
Topics: Adipose Tissue; Animals; Losartan; Male; Mice; Mice, Inbred mdx; Mice, Transgenic; Muscle, Skeletal; | 2015 |
Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.
Topics: Animals; Disease Models, Animal; Dystrophin; Exons; Losartan; Male; Mice; Mice, Inbred mdx; Muscle, | 2014 |
Chronic effects of losartan on the muscles and the serologic profiles of mdx mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Losartan; Male; | 2015 |
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Cell Adhesion Mo | 2011 |
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Fibrillin-1; Fib | 2007 |
ACE inhibitor bulks up muscle.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Losartan; Marfan Syndrome; Mice; Models, Biologica | 2007 |
Studies point way to new therapeutic prospects for muscular dystrophy.
Topics: Animals; Codon, Nonsense; Dystrophin; Gene Expression; Humans; Losartan; Marfan Syndrome; Mice; Musc | 2007 |